A study of hepatitis C treatments and other medications
Part of Digestive system, Infections clinical trials.
This trial looks at how two hepatitis C treatments (GLE/PIB or SOF/VEL) interact with other drugs or recreational substances. It may help doctors understand how to better manage treatment for people taking multiple medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must not have taken any hepatitis C treatment before starting this one
- You must have taken GLE/PIB or SOF/VEL between April 2018 and July 2023
- You must have used at least one other medication or recreational drug during that time
- You must have been treated at a hospital with electronic records that connect to your regular doctor
- You cannot have been treated at a private healthcare facility
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a pill combination (sofosbuvir/velpatasvir) to cure hepatitis C. It aims to make treatment simple and accessible, and you can join even if you've had treatment before (if it failed or you got reinfected).
This study compares two ways to treat hepatitis C: getting treatment at a local clinic near you, or the usual care at a central hospital. It aims to see if treatment at local clinics is safe, effective, and more convenient for patients.
This study checks how a new hepatitis C medicine (bemnifosbuvir/ruzasvir) interacts with medications used for opioid addiction, such as buprenorphine/naloxone or methadone. It helps doctors understand if the new medicine is safe and effective for people taking these addiction treatments.
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
This study offers a once-daily pill (Epclusa) to treat hepatitis C for people in jail who have never taken HCV medicine before. The goal is to see if starting treatment while incarcerated and continuing after release can cure the infection.
This trial looks at hepatitis C treatment for people whose last antiviral medicines did not fully clear the virus. It may help by testing a study drug approach for people in Pakistan who still have active hepatitis C infection.
Hear when a new HCV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.